As researchers have found that the majority of throat cancers are linked to HPV, the human papillomavirus, they have also found that patients with HPV-positive cancer tend to respond better to treatments than those with HPV-negative cancers. In fact, research is ongoing to see if reducing the intensity of these treatments in HPV-positive patients could result in equally good outcomes with fewer toxic side effects.
What if there was something you could do to prevent someone you love from hearing the words “you have cancer”? If you have never been diagnosed with cancer (not including basal or squamous cell skin cancer), THERE IS! Consider volunteering for the American Cancer Society’s Cancer Prevention Study-3.
If you have access to the U-M campus, including University Hospital, you can make an appointment for one of three enrollment sessions:
October 30, 10 a.m. – 1:30 p.m., University Hospital Cafeteria
October 31, 10 a.m. – 1:30 p.m., North Campus Research Complex on Plymouth Road Continue reading
Ovarian cancer is an aggressive disease that has a profound impact on the women who battle it and the families who support them
Approximately 1 in 70 women, or 1.4%, will be diagnosed with ovarian cancer in their lifetime. In most cases in the United States, a woman’s ovarian cancer is not diagnosed until it is in the later stages of the disease. At that point, few women are able to live longer than five years. In contrast, women whose ovarian cancer is diagnosed at earlier stages have up to a 90% chance of long term survival. As a result, ovarian cancer research continues to focus on ways to detect ovarian cancer when it is still in the earliest stages to give women the best chance to survive.
Ovarian cancer and early detection
There are many challenges to detecting ovarian cancer early. Each year in the United States approximately 1 in 2,500 women Continue reading
The U.S. Supreme Court on Thursday ruled unanimously that isolated human genes cannot be patented. The gene patents case involved Myriad Genetics, the company that holds patents on the BRCA1 and BRCA2 genes, which are linked to high risk of breast and ovarian cancer.
We talked to Sofia D. Merajver, M.D., Ph.D., director of the Breast and Ovarian Risk Evaluation Program at the University of Michigan Comprehensive Cancer Center, who has been doing research on hereditary breast and ovarian cancer for 20 years.
mCancer Partner: What does this ruling mean? Continue reading
Are certain drugs more effective against some types of prostate cancers than others? Researchers know that not all therapies work for all patients – the next question is to figure out how to match the right treatments with the right patients.
A new clinical trial is testing whether an experimental drug can maximize the effect of current treatment and whether matching that drug to a genetic anomaly can lead to better, more personalized treatment for prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout the country. Continue reading
As a Cancer AnswerLine nurse, I’m often asked by a caller, “Can I have treatment for my cancer with stem cells? I have read that U-M is involved with stem cell research.” This simple question has a very complex answer.
All of the blood cells in your body start out as young (immature) cells called hematopoietic, (or blood-forming), stem cells.
Stem cells mostly live in the bone marrow (the spongy center of certain bones), where they divide to make new blood cells. Once blood cells are mature they leave the bone marrow and enter the bloodstream. A small number of stem cells also get into the bloodstream. These are called peripheral blood stem cells. Continue reading